Proteomics enables the global and targeted analysis of all proteins and their functional states. Proteins are central to most biological functions within an organism and frequently alter in their abundance and in their activation status in disease. Thus, proteins can be identified as new candidates for novel diagnostic and therapeutic approaches and consequently routinely used as disease biomarkers as well as drug targets.
„Clinical Mass Spectrometry for Precision Medicine”
Prof. Ulrich Keilholz will present an overview about the newly established BMBF-funded MSTARS (“Multimodal Clinical Mass Spectrometry to Target Treatment Resistance”) consortium. The MSTARS research core in Berlin fosters precision medicine by establishing a mass spectrometry based platform in the clinics that allows standardized and high throughput analysis of patient material to support therapy recommendations.
"Comprehensive Discovery Proteomics Enables Biomarker and Therapeutic Target Identification"
Dr. Philipp Mertins will highlight new developments for mass spectrometry-driven proteomics in his MSTARS research group and present on applications in the field of hematological and head and neck cancers, that also connect to a project initiated within the translational Multi-omics hub of the Berlin Institute of Health (BIH).